Items Supported by the CCF Medical Assistance Programmes


(a) Drugs Supported by the First Phase Programme
(b) Drugs Supported by the Programme “Subsidy for Eligible Patients to Purchase Ultra-expensive Drugs (Including Those for Treating Uncommon Disorders)”
(c) Implantable Medical Devices Supported by the Programme “Subsidy for Eligible Patients of Hospital Authority to Purchase Specified Implantable Medical Devices for Interventional Procedures”

(a)

Drugs Supported by the First Phase Programme

The following specific self-financed cancer drugs are supported by the first phase programme:-

Item Drug Designated type
of cancer
Designated clinical indication
1 Abiraterone# Prostate cancer For metastatic castration resistant prostate cancer progressed on or after docetaxel-based chemotherapy regimen
2 Alectinib# Lung cancer For the treatment of patients with ALK-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on Crizotinib and intolerant to Ceritinib, or who have CNS-progression after Crizotinib
3 Axitinib# Renal cell carcinoma For patients with advanced renal cell carcinoma (RCC), whose disease has progressed on or after first-line treatment
4 Bendamustine Leukaemia Treatment of Chronic Lymphocytic Leukaemia (CLL) in patients who are unable to tolerate Fludarabine-based chemotherapy OR are refractory to Fludarabine
5a Bevacizumab Colorectal cancer First line treatment of RAS mutant metastatic colorectal cancer in combination with chemotherapy in patients indicated for intensive treatment OR First line treatment of RAS wild type metastatic colorectal cancer in combination with chemotherapy in patients indicated for intensive treatment who are unsuitable for or intolerant to Cetuximab / Panitumumab
5b Epithelial ovarian / fallopian tube / primary peritoneal cancer With carboplatin and paclitaxel for front-line advanced epithelial ovarian / fallopian tube / primary peritoneal cancer
6 Ceritinib# Lung cancer For adult patients with ALK-positive advanced NSCLC previously treated with Crizotinib
7a Enzalutamide# Prostate cancer For metastatic castration resistant prostate cancer progressed on or after docetaxel-based chemotherapy regimen
7b For the treatment of adult men with metastatic castration resistant prostate cancer (mCRPC) who are unsuitable for Docetaxel treatment on the basis of predicted intolerance to Docetaxel^
8 Everolimus# Breast cancer For HR+ve HER2-ve advanced breast cancer, in combination with Exemestane, in postmenopausal women with bone-only disease after recurrence or progression following a non-steroidal aromatase inhibitor
9 Lapatinib Breast cancer HER2+ve advanced breast cancer with prior therapy including an anthracycline, a taxane, and Trastuzumab
10 Nivolumab Skin cancer As monotherapy for BRAF V600 wild-type unresectable or metastatic melanoma
11 Obinutuzumab Leukaemia In combination with Chlorambucil for treatment of previously untreated chronic lymphocytic leukaemia (CLL) in adult patients with comorbidities making them unsuitable for full-dose Fludarabine or Bendamustine based therapy
12 Osimertinib# Lung cancer For the treatment of adult patients with EGFR T790M mutation-positive brain metastases from NSCLC who has progressed after previous treatment with an EGFR tyrosine
kinase inhibitor
13 Palbociclib# Breast cancer For treatment of HR+ve, HER2-ve metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine based therapy in post-menopausal patients with
visceral disease but not in visceral crisis
14 Pazopanib Renal cell carcinoma First line treatment for advanced renal cell carcinoma
15 Pegylated liposomal Doxorubicin Ovarian cancer Second line of platinum refractory or subsequent treatment of platinum resistant advanced ovarian cancer
16 Pertuzumab Breast cancer In combination with trastuzumab and docetaxel (taxane) in human epidermal growth factor receptor 2 protein (HER2) +ve metastatic or locally recurrent unresectable breast cancer patients with no prior anti-HER2 or chemotherapy for their metastatic disease
17 Ribociclib^# Breast cancer For treatment of HR+ve, HER2-ve metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine based therapy in post-menopausal patients with visceral disease but not in visceral crisis
18 Sorafenib Liver cancer Hepatocellular carcinoma (HCC) : ineligible for resection, transplant or loco-regional therapy
19a Sunitinib Renal cell carcinoma

First line treatment for advanced renal cell carcinoma

19b Gastrointestinal tumour Unresectable or metastatic gastrointestinal stromal tumour after failure or intolerance to Imatinib
20 Trastuzumab Gastric carcinoma Combined with Cisplatin & Capecitabine or 5FU for HER2 overexpressed metastatic gastric disease (IHC2+ and confirmatory FISH+ result, or IHC3+) in treatment-naive patients for their metastatic disease
21 Trastuzumab
emtansine
(T-DM1)
Breast cancer As monotherapy for HER2+ve metastatic breast cancer with prior Trastuzumab and/or taxane therapy for their metastatic disease
22 Vemurafenib Skin cancer As monotherapy for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma

^ With effect from 13 July 2019.
# The concerned drugs are under Capping Programmes where free drugs are subsequently provided through designated community pharmacy. For details, please refer to the [Information Sheet].

Self-financed Drugs supported by the Samaritan Fund (SF) and Community Care Fund (CCF) Medical Assistance Programme (First Phase Programme) (for specified self-financed cancer drugs)

Types of Diseases Clinical Indications Drugs SF CCF Medical Assistance Programme
(1st Phase Programme)
Haematology Acute lymphoblastic leukaemia Dasatinib  
Chronic immune thrombocytopenia Eltrombopag  
Chronic lymphocytic leukaemia Rituximab  
Bendamustine, Obinutuzumab  
Chronic myeloid leukaemia Dasatinib,
Nilotinib
 
Follicular lymphoma

Obinutuzumab^,
Rituximab

 
Mantle cell lymphoma Ibrutinib^#  
Multiple myeloma Bortezomib,
Lenalidomide
 
Multiple myeloma / Non-Hodgkin's lymphoma Plerixafor  
Myelodysplastic syndromes / chronic myelomonocytic leukaemia / acute myeloid leukaemia Azacitidine  
Respiratory Medicine Idiopathic pulmonary fibrosis Nintedanib (Ofev)^#  
Rheumatology Active systemic juvenile idiopathic arthritis Tocilizumab  
Ankylosing spondylitis Adalimumab,
Certolizumab Pegol, Etanercept,
Golimumab,
Infliximab,
Secukinumab
 
Juvenile idiopathic arthritis Adalimumab,
Etanercept,
Tocilizumab
 
Psoriatic arthritis Adalimumab,
Certolizumab Pegol, Etanercept,
Golimumab,
Infliximab,
Secukinumab,
Ustekinumab

 
Rheumatoid arthritis Abatacept,
Adalimumab,
Certolizumab Pegol, Etanercept,
Golimumab,
Infliximab,
Tocilizumab,
Tofacitinib
 
Refractory rheumatoid arthritis Rituximab  
Severe, active non-life-threatening granulomatosis with polyangiitis / microscopic polyangiitis Rituximab  
Neurology Relapsing remitting multiple sclerosis Alemtuzumab,
Natalizumab
 
Oncology Breast cancer Trastuzumab  
Everolimus#,
Lapatinib,
Palbociclib#,
Pertuzumab,
Ribociclib^#,
Trastuzumab emtansine
 
Colorectal cancer Cetuximab,
Panitumumab
 
Bevacizumab  
Gastric carcinoma Trastuzumab  
Gastrointestinal tumour Sunitinib  
Gastrointestinal stromal tumour Imatinib  
Recurrent high grade glioma Temozolomide  
Liver cancer Sorafenib  
Lung cancer Ceritinib*#, ^
Afatinib**,
Crizotinib#,
Erlotinib~,
Gefitinib~
 
Alectinib#,
Osimertinib#
 
Malignant lymphoma Rituximab  
Ovarian cancer Pegylated liposomal Doxorubicin  
Epithelial ovarian /
fallopian tube /
primary peritoneal cancer
Bevacizumab  
Prostate cancer Abiraterone#,
Enzalutamide#
 
Renal cell carcinoma Axitinib#,
Sunitinib,
Pazopanib
 
Skin cancer Nivolumab,
Vemurafenib
 
Gastroenterology Severe ulcerative colitis Infliximab,
Vedolizumab
 
Ophthalmology Non-infectious intermediate, posterior and panuveitis Adalimumab  
Endocrinology Dwarfism Growth Hormone  
Dermatology Severe psoriasis Adalimumab,
Etanercept,
Infliximab,
Secukinumab,
Ustekinumab
 
Others Chronic granulomatous disease Interferon  
Cryopyrin-associated periodic syndromes Canakinumab  

Remarks:

^ With effect from 13 July 2019.
* The designated clinical indications of the same drug supported by different funds are different. Please consult your case doctor for details.
** Afatinib is for first-line treatment for patients with activating EGFR mutation positive non-small cell lung cancer. The drug/indication was repositioned from CCF Medical Assistance Programme (First Phase Programme) to SF with effect from 16 February 2019. New applications and renewal applications approved on or after the effective date were subsidized by SF. For applications already approved before the effective date, CCF subsidy were provided until end of treatment of the applications.
~ Erlotinib and Gefitinib are for first-line and second-line treatment for patients with activating EGFR mutation positive non-small cell lung cancer. First-line treatment was repositioned from CCF Medical Assistance Programme (First Phase Programme) to SF with effect from 16 February 2019. New applications and renewal applications approved on or after the effective date were subsidized by SF. For applications already approved before the effective date, CCF subsidy were provided until end of treatment of the applications.
# The concerned drugs are under Capping Programmes where free drugs are subsequently provided through designated community pharmacy. For details, please refer to the [Information Sheet].

(b)

Drugs Supported by the Programme “Subsidy for Eligible Patients to Purchase Ultra-expensive Drugs (Including Those for Treating Uncommon Disorders)”

Item Drug Designated clinical indication
1a Eculizumab Paroxysmal Nocturnal Haemoglobinuria
1b Atypical haemolytic uraemic syndrome
2 Nusinersen Infantile Onset Spinal Muscular Atrophy (SMA) /
Childhood Onset Spinal Muscular Atrophy (SMA)
3 Tafamidis

For the treatment of transthyretin amyloidosis in adult patients
with stage 1 symptomatic polyneuropathy to delay peripheral neurologic impairment
(With effect from 13 July 2019)


(c)

Implantable Medical Devices Supported by the Programme “Subsidy for Eligible Patients of Hospital Authority to Purchase Specified Implantable Medical Devices for Interventional Procedures”

  1. Transcatheter Aortic Valve Implantation (TAVI)
  2. MitraClip System
  3. Percutaneous Pulmonary Valve Implantation (PPVI)
  4. Subcutaneous Implantable Cardioverter Defibrillator (S-ICD)
  5. Impella
  6. Valve-in-Valve Transcatheter Aortic Valve Implantation (VIV – TAVI) (with effect from 13 July 2019)

Patients who have financial difficulties may apply for assistance from the CCF. Eligible applicants may be given full or partial subsidy of the cost, depending on their financial situation.

For details of the Samaritan Fund, please refer to the Samaritan Fund web page in the Hospital Authority Website.